| 产品详情 |
| Edit |   |
|---|
| Product Name | Pramipexole Dihydrochloride |
|---|
| Description | Purity ~99% (HPLC). Non-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100mM water and 100mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). Solubility: H2O Primary Target: D3 Primary Target Ki: 0.5nM |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Pramipexole Dihydrochloride (Pramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-N'-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine Dihydrochloride) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217693 |
|---|
| Price | |
|---|
| Order / More Info | Pramipexole Dihydrochloride from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|